Waldenstrom Macroglobulinemia: Review of Pathogenesis and Management

被引：31

作者：

Yun, Seongseok ^{[1
,2
]}

Johnson, Ariel C. ^{[3
]}

Okolo, Onyemaechi N. ^{[1
]}

Arnold, Stacy J. ^{[4
]}

McBride, Ali ^{[5
]}

Zhang, Ling ^{[6
]}

Baz, Rachid C. ^{[2
]}

Anwer, Faiz ^{[7
]}

机构：

[1] Univ Arizona, Dept Med, Tucson, AZ USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol & Oncol, Tampa, FL USA

[3] Univ Arizona, Coll Med, Tucson, AZ USA

[4] Univ Arizona, Dept Med, Div Pathol, Tucson, AZ USA

[5] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol & Lab Med, Tampa, FL USA

[7] Univ Arizona, Dept Med, Div Hematol Oncol Blood & Marrow Transplantat, Tucson, AZ USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 05期

基金：

美国国家卫生研究院;

关键词：

CXCR4; Lymphoid neoplasm; Lymphoplasmacytic lymphoma; Monoclonal immunoglobulin M; MYD88; PHASE-II TRIAL; CONSENSUS PANEL RECOMMENDATIONS; EXTENDED RITUXIMAB THERAPY; 2ND INTERNATIONAL WORKSHOP; L265P SOMATIC MUTATION; WEEKLY BORTEZOMIB; LYMPHOPLASMACYTIC CELLS; INHIBITOR EVEROLIMUS; UNTREATED PATIENTS; CLINICAL-TRIAL;

D O I：

10.1016/j.clml.2017.02.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Waldenstrom macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：252 / 262

页数：11

共 67 条

[1] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study [J].

Ansell, Stephen M. ;

Tang, Hui ;

Kurtin, Paul J. ;

Koenig, Patricia A. ;

Inwards, David J. ;

Shah, Keith ;

Ziesmer, Steven C. ;

Feldman, Andrew L. ;

Rao, Radha ;

Gupta, Mamta ;

Erlichman, Charles ;

Witzig, Thomas E. .

LANCET ONCOLOGY, 2011, 12 (04) :361-368

[2] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma. [J].

Ansell, Stephen M. ;

Tang, Hui ;

Kurtin, Paul ;

Koenig, Patricia ;

Inwards, David J. ;

Shah, Keith ;

Witzig, Thomas E. .

BLOOD, 2009, 114 (22) :664-665

[3] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) [J].

Buske, C. ;

Hoster, E. ;

Dreyling, M. ;

Eimermacher, H. ;

Wandt, H. ;

Metzner, B. ;

Fuchs, R. ;

Bittenbring, J. ;

Woermann, B. ;

Hohloch, K. ;

Hess, G. ;

Ludwig, W-D ;

Schimke, J. ;

Schmitz, S. ;

Kneba, M. ;

Reiser, M. ;

Graeven, U. ;

Klapper, W. ;

Unterhalt, M. ;

Hiddemann, W. .

LEUKEMIA, 2009, 23 (01) :153-161

[4] Rituximab therapy in Waldenstrom's macroglobulinemia:: Preliminary evidence of clinical activity [J].

Byrd, JC ;

White, CA ;

Link, B ;

Lucas, MS ;

Velasquez, WS ;

Rosenberg, J ;

Grillo-López, AJ .

ANNALS OF ONCOLOGY, 1999, 10 (12) :1525-1527

[5] The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia [J].

Cao, Y. ;

Hunter, Z. R. ;

Liu, X. ;

Xu, L. ;

Yang, G. ;

Chen, J. ;

Patterson, C. J. ;

Tsakmaklis, N. ;

Kanan, S. ;

Rodig, S. ;

Castillo, J. J. ;

Treon, S. P. .

LEUKEMIA, 2015, 29 (01) :169-176

[6] Initial genome sequencing and analysis of multiple myeloma [J].

Chapman, Michael A. ;

Lawrence, Michael S. ;

Keats, Jonathan J. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Schinzel, Anna C. ;

Harview, Christina L. ;

Brunet, Jean-Philippe ;

Ahmann, Gregory J. ;

Adli, Mazhar ;

Anderson, Kenneth C. ;

Ardlie, Kristin G. ;

Auclair, Daniel ;

Baker, Angela ;

Bergsagel, P. Leif ;

Bernstein, Bradley E. ;

Drier, Yotam ;

Fonseca, Rafael ;

Gabriel, Stacey B. ;

Hofmeister, Craig C. ;

Jagannath, Sundar ;

Jakubowiak, Andrzej J. ;

Krishnan, Amrita ;

Levy, Joan ;

Liefeld, Ted ;

Lonial, Sagar ;

Mahan, Scott ;

Mfuko, Bunmi ;

Monti, Stefano ;

Perkins, Louise M. ;

Onofrio, Robb ;

Pugh, Trevor J. ;

Rajkumar, S. Vincent ;

Ramos, Alex H. ;

Siegel, David S. ;

Sivachenko, Andrey ;

Stewart, A. Keith ;

Trudel, Suzanne ;

Vij, Ravi ;

Voet, Douglas ;

Winckler, Wendy ;

Zimmerman, Todd ;

Carpten, John ;

Trent, Jeff ;

Hahn, William C. ;

Garraway, Levi A. ;

Meyerson, Matthew ;

Lander, Eric S. ;

Getz, Gad ;

Golub, Todd R. .

NATURE, 2011, 471 (7339) :467-472

[7] Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenstrom's Macroglobulinemia [J].

Ciccarelli, Bryan T. ;

Patterson, Christopher J. ;

Hunter, Zachary R. ;

Hanzis, Christina ;

Ioakimidis, Leukothea ;

Manning, Robert ;

Yang, Guang ;

Xu, Lian ;

Zhou, Yangsheng ;

Sun, Jenny ;

Liu, Xia ;

Tseng, Hsiuyi ;

Cao, Yang ;

Sheehy, Patricia ;

Rodig, Scott J. ;

Treon, Steven P. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01) :160-163

[8] Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003 [J].

Dhodapkar, Madhav V. ;

Hoering, Antje ;

Gertz, Morie A. ;

Rivkin, Saul ;

Szymonifka, Jackie ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2009, 113 (04) :793-796

[9] Waldenstrom's macroglobulinemia: Clinical features, complications, and management [J].

Dimopoulos, MA ;

Panayiotidis, P ;

Moulopoulos, LA ;

Sfikakis, P ;

Dalakas, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :214-226

[10] Diagnosis and management of Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Kyle, RA ;

Anagnostopoulos, A ;

Treon, SP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1564-1577

← 1 2 3 4 5 6 7 →